Literature DB >> 26300499

Atypical pituitary adenomas: 10 years of experience in a reference centre in Portugal.

F Tortosa1, S M Webb2.   

Abstract

INTRODUCTION: Primary pituitary tumours are classified by the World Health Organization as typical adenoma, atypical adenoma, or carcinoma. Information on the incidence and prevalence of these pituitary tumours is limited, and these data in Portugal are scarce, obsolete, or non-existent. Our study evaluates pituitary adenomas (PA) in the population of Lisbon, and it aims to describe the prevalence of all subgroups in order to revise the incidence of the 'atypical' histological type and its correlation to tumour subtype, invasion, and recurrence. PATIENTS AND METHODS: A retrospective, descriptive analysis of patients with PA diagnosed between 2004 and 2013 was performed at Santa Maria University Hospital, a national reference centre.
RESULTS: Of the 220 PA cases diagnosed, 28 (12.7%) fulfilled criteria for atypical lesions, and within that group, 23 were macroadenomas (82.1%) and 13 showed radiological evidence of invasion (46.4%). Ages ranged from 29 and 81 years (mean, 53.4 years). Eleven patients (39.3%) had functional tumours. Sixteen of the 28 patients (57.1%) experienced tumour recurrences; in the 100 adenomas monitored for more than 5 years, the recurrence rate in atypical PA was 7 times higher than in typical PA. Immunohistochemically, 28.6% of the tumours stained positively for ACTH, 25% for gonadotrophins, and 17.9% for prolactin. The proliferation index (Ki67) ranged from 3% and 25% (mean, 6.4%).
CONCLUSIONS: Atypical PAs make up 12.7% of all surgically treated PA cases, and they tend to be invasive and recurrent macroadenomas. We found no differences in metastatic potential between typical and atypical PA.
Copyright © 2015 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Adenoma hipofisario; Antigen Ki-67; Antígeno Ki67; Atypical; Atípico; Pituitary adenoma

Mesh:

Year:  2015        PMID: 26300499     DOI: 10.1016/j.nrl.2015.06.010

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  7 in total

Review 1.  Management of aggressive growth hormone secreting pituitary adenomas.

Authors:  Daniel A Donoho; Namrata Bose; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

2.  P21Waf1/Cip1 and p27Kip1 are correlated with the development and invasion of prolactinoma.

Authors:  Wei Dong; Jianhua Li; Qian Liu; Chunhui Liu; Chuzhong Li; Guidong Song; Haibo Zhu; Hua Gao; Yazhuo Zhang
Journal:  J Neurooncol       Date:  2017-12-11       Impact factor: 4.130

3.  Predictive modeling for pituitary adenomas: single center experience in 501 consecutive patients.

Authors:  A L Pappy; A Savinkina; C Bicknese; S Neill; N M Oyesiku; A G Ioachimescu
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

4.  Surgical treatment for male prolactinoma: A retrospective study of 184 cases.

Authors:  Yi-Jun Song; Mei-Ting Chen; Wei Lian; Bing Xing; Yong Yao; Ming Feng; Ren-Zhi Wang
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

5.  Bony lesions of cranium and spine: A study of 123 cases.

Authors:  Ashvini Amol Kolhe; Asha Sharad Shenoy; Abhishek S Laul; Naina A Goel
Journal:  J Craniovertebr Junction Spine       Date:  2020-11-26

6.  The Past, Present, and Future Statuses of Formerly Classified "Atypical Pituitary Adenomas": A Clinicopathological Assessment of 101 Cases in a Cohort of More than 1,000 Pure Endoscopically Treated Patients in Single Center.

Authors:  Ercan Bal; İbrahim Kulaç; Selim Ayhan; Figen Söylemezoğlu; Mustafa Berker
Journal:  J Neurol Surg B Skull Base       Date:  2020-02-20

7.  The Predictive Value of Pathologic Features in Pituitary Adenoma and Correlation with Pituitary Adenoma Recurrence.

Authors:  Jee Soon Kim; Youn Soo Lee; Min Jung Jung; Yong Kil Hong
Journal:  J Pathol Transl Med       Date:  2016-10-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.